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1. Introduction 
Ovarian cancer is the fifth most common cancer among women and approximately 
200,000 women are diagnosed as ovarian cancer every year in the world (Parkin et al., 
2005). Platinum-containing chemotherapeutic agents such as cisplatin (cis-
diamminedichloroplatinum II) and carboplatin have been most frequently used for the 
treatment of ovarian cancer. These platinum compounds specifically react with guanine 
residues in DNA to form interstrand and intrastrand cross-links in DNA, known as DNA-
adducts. This interferes with mitosis of cancer cells and causes cell death. However, ovarian 
cancer cells can become resistant to cisplatin and the majority of patients develop cisplatin-
resistant disease (Giaccone 2000; Hennessy et al., 2009; Kartalou & Essigmann 2001), and as 
a result, most ovarian cancers relapse. Paclitaxel (taxol) and two analogues of camptothecin, 
irinotecan and topotecan, are the drugs most commonly administered to platinum-resistant 
ovarian cancer patients. Paclitaxel (taxol) binds to -tubulin and stabilizes microtubule 
structure, which causes a G2/M block in the cancer cell cycle. Irinotecan, also known as 
CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy camptothecin) and 
topotecan (10-hydroxy-9-dimethylaminomethyl-(S)-camptothecin) inhibit topoisomerase I 
by resealing DNA breaks, which results in the inhibition of cancer cell growth (Bookman et 
al., 1998; Swisher et al., 1997). However, the survival rate for relapsed patients is low; Thus, 
there is an urgent need for more effective chemotherapeutic approaches for ovarian cancer 
treatment. We have previously reported that some ovarian cancer cell lines are remarkably 
sensitive to vitamin K2 (Shibayama-Imazu et al, 2003, 2006, 2008). In this review, strategies 
for developing chemotherapeutic agents for ovarian cancer are described and vitamin K2 is 
proposed as a promising chemotherapeutic agent for ovarian cancer. 
2. Effect of vitamin K2 on cancer cells 
Natural forms of vitamin K such as vitamin K1 (phylloquinone) and vitamin K2 
(menaquinones, MK) are cofactors for the post-translational -carboxylation of glutamate 
residues in vitamin K-dependent proteins (Fig. 1). Vitamin K is mainly used as a hemostatic 
agent because coagulation factors VII, IX, and X, which are critical to blood coagulation, are 
vitamin K-dependent proteins. In addition, vitamin K2 has anti-cancer activity, whereas 
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vitamin K1 does not. This difference arises from structural differences in the side chains 
attached to the parent ring of vitamin K. 
2.1 Structures and fundamental properties of vitamin K 
The parent ring structure of vitamin K is 2-methyl-1,4-naphthoquinone (menadione), which is 
also known as vitamin K3 (Fig. 1). Vitamin K3 does not occur naturally and causes oxidative 
stress in both normal and cancer cells and is toxic to the liver. There are few successful clinical 
applications of vitamin K3. Vitamin K1 has a phythyl side chain at the 3 position of vitamin K3 
and is present mainly in green vegetables. Vitamin K1 is converted to vitamin K2 in animals 
and humans (Thijssen & Drittij-Reijnders, 1996); vitamin K2 has isoprenoid side chains of 
various lengths attached to the 3 position of the vitamin K3 ring structure. The different forms 
of vitamin K2, menaquinone-n (MK-n), are categorized according to the number of repeating 
isoprenoid residues in the side chain. The most common form of vitamin K2 in animals is 
menaquinone-4 (MK-4), which has four isoprenoid residues as its side chain. MK-4 is the most 
biological active form of the vitamin and is produced by intestinal bacteria. Long chain 
menaquinones, MK-7 to MK-10, are synthesized by bacteria and are present in fermented 
products such as cheese (MK-8 and MK-9) and East Asian fermented soybean products, such 
as natto and miso (Shearer et al., 1996; Schurgers & Vermeer, 2000).  
 
 
Fig. 1. Chemical Structures of vitamin K 
Naturally occurring vitamin K1 contains a phytyl group, and vitamin K2 has a repeating 
isoprenoid group at the 3 position of the vitamin K3 menadione ring. In animals, the most 
common and most biologically active form of vitamin K2 is MK-4, which has four 
isoprenoid residues (n = 4). Unlike vitamin K1, vitamin K2 has anti-cancer activity in 
addition to its critical role in blood coagulation and bone metabolism. The isoprenyl side 
chain of vitamin K2 contributes to its unique anti-cancer activity.  
2.2 Growth inhibitory activity of vitamin K2 on cancer cells 
We initially demonstrated vitamin K2-induced differentiation in human leukemia cells 
which was unrelated to its clinical role in blood coagulation and bone metabolism (Sakai I, 
1994). Inhibition of cancerous cell growth and induction of apoptosis by vitamin K2 has 
subsequently been observed in a variety of human cancer cell lines, including liver 
(Nishikawa et al., 1995; Otsuka et al., 2004), pancreatic (Shibayama-Imazu et al., 2003), 
ovarian (Shibayama-Imazu et al., 2003, 2006, 2008), lung (Yoshida et al., 2003; Yokoyama et 
al., 2005), stomach (Tokita et al., 2006), breast (Wu et al., 1993), and leukocyte (Yaguchi, 
1997). The growth-inhibitory effects of vitamin K2 on various human cancer cell lines are 
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et al., 2001), and inhibition of cancerous cell growth was not observed with vitamin K1. 
Therefore, the side chain of vitamin K2 may be important for the anti-cancer activity of 
vitamin K2. The anti-cancer activity of isoprenoids is known to depend on the length of the 
polyprenyl alcohol side chain; polyprenoids with a geranylgeranyl group or a 
geranylisopropyl group have the most potent anticancer activity (Ohizumi et al., 1995). 
Vitamin K2 MK-4 has a geranylgeranyl side chain and is commonly used for the treatment 
of a variety of cancer cells. In this review, vitamin K2 MK-4 is denoted simply as vitamin K2. 
 
 
Table 1. IC50 values for vitamin K2 in various cancer cell lines. IC50 is defined as the 
concentration of vitamin K2 that inhibits cell growth by 50%. The values for SW626 and 
OVCAR3 were estimated from previously published results (Shibayama-Imazu et al., 2008). 
Clinical trials using vitamin K2 that were conducted successfully for leukemia and liver 
cancer patients are indicated by boxes. 
3. Induction of apoptosis in ovarian cells by vitamin K2 
Inhibition of cell growth is a good indicator of the induction of apoptosis in cancer cells by 
chemical agents. A comparison of the inhibition of the growth of various cancer cells by 
vitamin K2 showed that an ovarian cancer cell line PA-1 is the most sensitive to vitamin K2. 
A steroid orphan receptor TR3/Nur77, which regulates cell proliferation and apoptosis, is 
responsible for the induction of apoptosis in ovarian cancer PA-1 cells by vitamin K2. 
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3.1 Growth inhibition of ovarian cancer cells by vitamin K2 
We observed that apoptosis is readily induced in some ovarian cancer cell lines by low 
concentrations of vitamin K2 (Shibayama-Imazu et al, 2003; 2006). Figure 2 shows that 
vitamin K2 is a potent inhibitor of the growth of human ovarian cancer PA-1 cells, with an 
IC50 of 5.0 + 0.7 M. The IC50 value for PA-1 cells is the lowest observed for cancer cell lines 
treated with vitamin K2, indicating that PA-1 cells are the most sensitive to vitamin K2 
(Table 1). In contrast to PA-1 cells, SK-OV-3 cells were resistant to vitamin K2 and no 
significant growth inhibition was observed (Fig. 2). PA-1 and SK-OV-3 cells were used as 
vitamin K2-sensitive and vitamin K2-resistant cells, respectively, in order to examine the 
mechanism of apoptosis induction by vitamin K2. 
 
 
Fig. 2. Effects of vitamin K2 on the growth of human ovarian cancer PA-1 and SK-OV-3 cells. 
Cell proliferation was determined using the XTT assay 96 h after treatment with various 
concentrations of vitamin K2. Each value is represented as mean + SD of the results from 
three independent experiments. Vitamin K2-sensitive PA-1(●); vitamin K2-resistant SK-OV-
3 (○). [Reproduced with permission from Fig. 1 of Shibayama-Imazu et al., 2008.] 
3.2 Mechanism of the induction of apoptosis by vitamin K2  
The induction of apoptosis by vitamin K2 in vitamin K2-sensitive ovarian cancer PA-1 cells 
proceeds slowly. Fragmented nucelosomes were released into the cytosolic fraction 24 h 
after the start of incubation of PA-1 cells with 30 M vitamin K2, and increased until at least 
72 h after the start of incubation (Fig. 3A). After 72 h, the induction of apoptosis was evident 
in approximately 35% of PA-1 cells, as determined by counting apoptotic cells with 
condensed and fragmented nuclei stained with Hoechst 33342 (Shibayama-Imazu et al., 
2008). The slow rate of apoptosis is one of the characteristic features of vitamin K2-induced 
apoptosis, compared to apoptosis induced by conventional anticancer agents such as 
camptothecin and etoposide, and by geranaylgeraniol (Masuda et al., 2000; Shibayama-
Imazu et al., 2003). Mitochondria play a crucial role in the induction of apoptosis by various 
apoptotic agents. Cytochrome c released from mitochondria forms a complex with Apaf-1 
and activates procaspase 9, which activates a downstream caspase cascade. Once the 
caspase cascade has been triggered, nucleases are activated to induce apoptotic chromatin 
condensation and DNA fragmentation. The release of cytochrome c in PA-1 cells was 
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detected 48 h after treatment with 30 M vitamin K2 and the release increased sharply 72 h 





Fig. 3. Induction of apoptosis in ovarian cancer PA-1 and SK-OV-3 cells by vitamin K2. (A) 
Both vitamin K2-sensitive PA-1 (●) and vitamin K2-resistant SK-OV-3 (○) cells were treated 
with 30 M of vitamin K2 for various times. Each value is represented as mean + SD of the 
results from three independent experiments. The percentage of apoptotic cells that 
contained condensed and fragmented chromatin was quantified after staining with Hoechst 
33342 as described previously (Shibayama-Imazu et al., 2008). (B) The panel shows 
immunoblotting analysis of cytochrome c released from mitochondria into the cytoplasm of 
PA-1 cells that had been treated with 30 M vitamin K2 (Shibayama-Imazu et al., 2008). 
[Reproduced with permission from Fig. 6 of Shibayama-Imazu et al., 2008.] 
3.3 Accumulation of TR3/Nur77 in mitochondria after treatment of PA-1 cells with 
vitamin K2 
A steroid orphan receptor TR3/Nur77 is overexpressed in various cancer cells lines, including 
ovarian (Holmes et al., 2002), lung (Li et al., 1998), prostate (Li et al., 2000), colon (Cho et al., 
2007), pancreatic (Chintharlapalli et al., 2005), bladder (Chintharlapalli et al., 2005) and 
stomach (Wu et al., 2002). The expression of TR3/Nur77 is rapidly induced during cancer cell 
apoptosis triggered by various apoptotic agents, such as phorbol ester 12-O-tetradecanoyl 
phobol-13-acetate (Li et al., 2000), etoposide (Li et al., 2000), cytosporone B (Liu et al., 2010), 
and the synthetic retinoid 6-[3-(1-admantyl)]-4-hydroxyphenyl]-2-naphthalene carboxylic acid 
(CD437, Holmes et al., 2004). TR3/Nur77 translocates from the nucleus to mitochondria in 
response to these apoptosis inducers, with the exception of CD437 (Li et al., 2000). TR3/Nur77 
binds to Bcl-2 which switches the function of Bcl-2 from protection to the induction of 
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cytochrome c release from the mitochondria, resulting in the induction of apoptosis (Li et al., 
2000). For CD437, the levels of TR3/Nur77 in the nuclei of various pancreatic cancer cells were 
increased by treatment with this agent, although translocation of TR3/Nur77 from the nuclei 
to the mitochondria was not observed (Chintharlapalli et al., 2005).  
 
 
Fig. 4. Immunoblotting analysis of TR3/Nur77 in vitamin K2-sensitive PA-1 cells and 
vitamin K2-resistant SK-OV-3 cells. Both vitamin K2-sensitive PA-1 and vitamin K2-resistant 
SK-OV-3 cells were treated with 30 M of vitamin K2 for 0 h, 24 h, 48 h, and 72 h. 
TR3/Nur77 in the cell lysates (A) and in the heavy mitochondrial fractions (B) were detected 
by immunoblotting using rabbit TR3/Nur77-specific polyclonal antibody (Shibayama-
Imazu et al., 2008). Two immunostained bands were detected under our electrophoretic 
conditions as previously reported (Chintharlapalli et al., 2005). The more slowly migrating 
minor band is phosphorylated TR3/Nur77 (Pekarsky et al., 2001). The intensities of the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) band and the cytochrome oxidase 
subunit Ⅳ (OX) band confirmed that an equal amount of cell lysate proteins and heavy 
mitochondrial fraction proteins, respectively, were loaded in each lane. [Reproduced with 
permission from Fig. 3 and Fig. 6 of Shibayama-Imazu et al., 2008.] 
The level of TR3/Nur77 in vitamin K2-sensitive PA-1 cells was approximately four-fold 
higher than that in vitamin K2-resistant SK-OV-3 cells (Fig. 4A). The level of TR3/Nur77 in 
the cell lysate of PA-1 cells increased markedly in a time-dependent manner after treatment 
with vitamin K2. In contrast, the level of TR3/Nur77 in the cell lysate of vitamin K2-
resistant SK-OV-3 cells was very low and was not significantly affected by treatment with 
vitamin K2. The TR3/Nur77 level in the cell lysate of SK-OV-3 cells did not reach the level 
observed in untreated PA-1 cells, even 72 h after the start of the treatment.  
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In the heavy mitochondrial fraction, which is composed mostly of mitochondria, the level of 
TR3/Nur77 increased sharply 48 h and 72 h after the start of the treatment of PA-1 cells with 
vitamin K2 (Fig. 4B). The percentage of apoptotic cells increased in parallel with the increase 
in TR3/Nur77 in the heavy mitochondrial fraction of PA-1 cells (Fig. 3A). In contrast, the 
level of TR3/Nur77 in the heavy mitochondrial fraction of vitamin K2-resistant SK-OV-3 
cells was unchanged by vitamin K2 treatment (Fig. 4B). Immunofluorescence staining of PA-
1 cells during vitamin K2-induced apoptosis indicates that the amounts of TR3/Nur77 
present in both mitochondria and nuclei as well as in the cytosolic fraction increased after 
vitamin K2 treatment (Shibayama-Imazu et al., 2008). This suggests that TR3/Nur77 
migrated directly from the cytoplasm to the mitochondria and no translocation from the 
nucleus to mitochondria occurred. It should be noted that this effect of vitamin K2 on 
ovarian cancer PA-1 cells is unique and different from that of apoptosis-inducing agents 
such as etoposide (Li et al., 2000) and cytosporone B (Liu et al., 2010) which cause 
translocation of TR3/Nur77 from the nuclei to the mitochondria. 
4. Strategy for the improvement of chemotherapy of ovarian cancer 
Combination treatments with agents that sensitize ovarian cancer cells to platinum 
compounds are an efficient strategy for overcoming chemoresistance acquired by ovarian 
cancer cells. Cancer cell survival signals can be inhibited by chemical agents, or ovarian 
cancer cells can be sensitized to platinum chemotherapeutic agents by preventing the repair 
of platinum-DNA adducts. A further method is to find chemical agents that induce 
apoptosis in ovarian cancer cells by a different mechanism from platinum compounds and 
may therefore exert synergistic apoptotic effects. 
4.1 Inhibition of survival signals  
The balance between cellular survival and induction of apoptosis determines the sensitivity 
of cancer cells to chemotherapeutic drugs. Therefore, blocking survival cascade signals or 
enhancing apoptosis-inducing signals enhances the sensitivity of ovarian cancer cells to 
chemotherapeutic agents (Vivanco & Sawyers, 2002). Topotecan, an inhibitor of 
topoisomerase I, inhibits Akt kinase activity in cisplatin-resistant ovarian cancer Caov-3 cells 
(Tsunetoh et al., 2010). The PI3K-Akt survival cascade signal in cisplatin-resistant ovarian 
cancer cells is inhibited by treatment with a combination of topotecan and cisplatin, which 
enhances the sensitivity to cisplatin in vitro and in vivo (Tsunetoh et al., 2010). The flavonoid 
compound, kaempherol, sensitizes ovarian cancer OVCAR-3 cells to cisplatin by down 
regulation of cMyc, which is involved in proliferation and is commonly activated in human 
cancer cells (Jung et al., 2008; Luo et al., 2010). Treatment of cisplatin resistant A2780CP 
ovarian cancer cells with a polyphenol, curcumin (diferulonyl methane), derived from the 
rhizomes of turmeric Curcuma longa, down regulated the expression of cMyc and pro-
survival proteins such as Bcl-XL and Mcl-1, leading to cisplatin sensitization (Yallapu, 2010). 
Topotecan, kaempherol, and curcumin therefore warrant further investigation as potential 
therapeutic agents for ovarian cancer. 
4.2 Inhibition of platinum-DNA adduct repair 
Inhibitors of DNA synthesis, such as gemcitabine (Touma et al., 2006), cytarabine (Swinnen 
et al., 2008), hydroxyurea (Raymond et al., 2001), and aphidicolin (Sargent et al., 1996), are 
able to inhibit the repair process of platinum-DNA adducts and have been used to increase 
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sensitivity to chemotherapeutic platinum compounds. A phase II study using carboplatin 
followed by gemcitabine and paclitaxel for the treatment of ovarian cancer patients showed 
an improvement in therapeutic efficacy (Harries et al., 2004). However, the pulmonary 
toxicity observed as a side effect of this treatment still needs to be addressed. 
The histone deacetylase inhibitor panobinostat, which affects the expression of various 
genes, showed synergistic cytotoxic effects in conjunction with conventional 
chemotherapeutic agents including carboplatin on ovarian cancer cell lines (Budman et al., 
2010).  
Arsenic trioxide inhibits UV-induced DNA repair processes (Hartwig et al., 1997), and also 
showed additive cytotoxic effects with cisplatin for human ovarian carcinoma cell lines in 
vitro (Uslu et al., 2000). Arsenic trioxide was successfully used for the treatment of all-trans 
retinoic acid resistant acute promyelocytic leukemia (Soignet et al., 1998), which suggests 
that it may be successful in treating cisplatin-resistant ovarian cancer patients. 
4.3 Induction of apoptosis in cancer cells by activating the TR3/Nur77 gene 
Indole -3-carbinol (I3C), contained in cruciferous vegetables such as broccoli, cabbage, and 
cauliflower, and its dimeric product 3,3’-diindolylmethane (DIM) are nontoxic, natural 
compounds with anticancer activities. DIM and its analogues increase the levels of 
TR3/Nur77 and induce apoptosis in various cancer cell lines including colon, pancreas, 
prostate, and breast cancer cells (Banerjee et al., 2009; Cho et al., 2007). Pancreatic cancer 
cells with acquired resistance to chemotherapeutic drugs, such as cisplatin, oxaliplatin, and 
gemcitabin, were sensitized by pretreatment with DIM (Banerjee et al., 2009). Compounds 
that activate the TR3/Nur77 gene and induce apoptosis in cancer cells are proposed as a 
new category of chemotherapeutic drugs, and include an analogue of cytosporone B (Liu et 
al., 2010) and 1,1-bis(3'-indolyl)-1-(p-substituted phenyl) methanes (C-substituted DIMs, 
Chintharlapalli et al., 2005). Acetylshikonin and its derivative 5,8-diacetoxyl-6-(1'-acetoxyl-
4'-methyl-3'-pentenyl)-1,4-naphthaquinones (SK07) increased the level of TR3/Nur77 
through posttranscriptional regulation, and induced apoptosis in various cancer cell lines 
including lung and cervical cancer cells (Liu et al., 2008). The positive correlation of the 
expression of the TR3/Nur77 subfamily member Nor-1 with survival rates of diffuse large 
B-cell lymphoma patients indicates the importance of TR3/Nur77 as a target for anti-cancer 
agents (Shipp et al., 2002). The importance of TR3-Nur77 as a therapeutic target of ovarian 
cancer is also demonstrated by the fact that low expression of TR3/Nur77 in tissue samples 
obtained from various cancer patients is significantly associated with metastasis of primary 
solid cancers (Ramaswamy et al., 2003). 
We discovered that some ovarian cancer cell lines, such as PA-1 cells, are sensitive to 
vitamin K2 and apoptosis induced by stimulation of TR3/Nur77 synthesis and its 
accumulation in mitochondria (Fig. 5). Small interfering RNA (siRNA) directed against TR3-
Nur77 (siRNA-TR3/Nur77) caused a marked decrease in the levels of TR3/Nur77 in the 
lysate of PA-1 cells. When ovarian cancer PA-1 cells after transfection with siRNA-
TR3/Nur77 were treated with vitamin K2, the marked increase in the levels of TR3/Nur77 
observed by vitamin K2 without siRNA-TR3/Nur77 was almost completely abolished 
(Shibayama-Imazu et al., 2008). Induction of apoptosis by vitamin K2 was also significantly 
inhibited by transfection of PA-1 cells with siRNA-TR3/Nur77. Furthermore, 
cycloheximide, an inhibitor of protein synthesis, prevented the increase in TR3/Nur77 
levels, its accumulation in the mitochondria, and the induction of apoptosis in PA-1 cells 
caused by vitamin K2 treatment (Shibayama-Imazu et al., 2008). These results indicate that 
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the synthesis of TR3/Nur77 and its accumulation in mitochondria are required for the 
induction of apoptosis in PA-1 cells by vitamin K2 and also suggest that an increase in the 
level of TR3/Nur77 could be the cause of sensitivity to the induction of apoptosis in PA-1 
cells by vitamin K2 (Fig. 5). 
 
 
Fig. 5. A model for the induction of apoptosis in vitamin K2-sensitive ovarian cancer cells. 
The levels of TR3/Nur77 in vitamin K2-sensitive ovarian cancer cells are increased after 
treatment with vitamin K2. TR3/Nur77 synthesized in the cytoplasm migrates to the 
mitochondria and binds to Bcl-2, which protects the cell from apoptosis. Interaction of 
TR3/Nur77 with Bcl-2 induces a conformational change in Bcl-2, triggering the release of 
cytochrome c, which activates the caspase cascade and thus induces apoptosis. siRNA-
TR3/Nur77 causes degradation of TR3/Nur77 mRNA and cycloheximide inhibits the 
protein synthesis of TR3/Nur77, both leading to inhibition of the induction of apoptosis by 
vitamin K2. 
A combination of vitamin K2 and conventional chemotherapeutic agents for ovarian cancer, 
such as cisplatin and etoposide, which induce apoptosis by different mechanisms, might have 
additive or synergistic apoptotic effects on ovarian cancer cells. In addition, pretreatment with 
vitamin K2 or combination treatment with conventional chemotherapeutic agents could be 
effective for overcoming chemoresistance in ovarian cancer cells.  
5. Vitamin K2 as a promising chemotherapeutic agent for ovarian cancer  
Vitamin K2 induces apoptosis in blastic cells from patients with myelodysplastic syndrome 
(Nishimaki et al., 1999; Yaguchi et al., 1998) and has been successfully used in the clinical 
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treatment of patients with this disorder (Miyazawa et al., 2000; Takami et al., 1999; Yaguchi 
et al., 1998, 1999). Oral administration of vitamin K2 with retinoic acid to a patient with 
relapsed acute promyelocytic leukemia resulted in complete remission (Fujita et al., 1998). In 
addition, oral administration of vitamin K2 also had a suppressive effect on the recurrence 
of hepatocellular carcinoma and improved patient survival rate (Habu et al., 2004; Mizuta et 
al., 2006; Tamori et al., 2007; Yoshiji et al., 2009). A recent cohort study indicates that cancer 
incidence and mortality were significantly decreased by dietary intake of vitamin K2 from 
food sources (Nimptsch et al., 2010). Vitamin K2 is also used clinically as a drug for 
osteoporosis in Asian countries such as Japan, Korea, and Thailand, because it also has a 
significant effect on bone fracture prevention (Cockayne et al., 2006; Olson, 2000; Shiraki et 
al., 2000). This is because calcium-binding proteins such as osteocalcin and calbindin, which 
are involved in calcium uptake and bone mineralization, are vitamin K-dependent proteins. 
A further cohort study indicated that the relative risk of coronary heart disease was also 
reduced by dietary intake of vitamin K2 (Geleijne et al., 2004). This may be because vitamin 
K-dependent proteins are associated with vascular repair processes (Benzakour & Kanthou, 
2000) and the prevention of vascular calcification (Shanahan et al, 1998). No side effects from 
vitamin K2 therapy were observed in any of these clinical studies; even vitamin K2 dosages 
in excess of 40 mg/day did not cause any side effects associated with hypercoagulable states 
(Shiraki et al., 2000), demonstrating its excellent safety profile. However, it is unknown why 
some ovarian cancer cell lines are resistant to vitamin K2. It may be possible to overcome 
vitamin K2 resistance by using it in combination with other agents that increase the level of 
TR3/Nur77 in cancer cells, such as DIM, cytosporone B, and the shikonin derivative SK07. 
SK07 stimulates the protein synthesis of TR3/Nur77 even in cervical cancer HeLa cells, in 
which the basal expression level of TR3/Nur77 is low (Liu et al., 2008). Further pre-clinical 
and clinical evaluation of vitamin K2 is required for its use in chemotherapy for ovarian 
cancers.  
6. Conclusion  
Several ovarian cancer cell lines are sensitive to vitamin K2; the IC50 value of the most vitamin 
K2-sensitive ovarian cancer PA-1 cells is as low as 5 M. Apoptosis is induced in PA-1 cells 
through the stimulation of TR3/Nur77 synthesis and its accumulation in mitochondria, which 
results in the release of cytochrome c and activation of the caspase cascade (Fig. 5). Because 
this mechanism is different from those of conventional chemotherapeutic agents for ovarian 
cancer such as cisplatin and etoposide, the present study demonstrates a new method for 
increasing the sensitivity of cisplatin resistant ovarian cancer cells to chemotherapy. Moreover, 
our observation suggests that the combination of vitamin K2 with cisplatin or etoposide may 
potentially be effective for the treatment of ovarian cancers. None of the clinical trials using 
high doses of vitamin K2 have recorded side effects from the treatment, and oral 
administration of vitamin K2 has already been successfully used for the treatment of acute 
promyelocytic leukemia and haepatocellular carcinoma (Table 1). We therefore propose 
vitamin K2 as a useful chemotherapeutic agent for ovarian cancer.  
7. Acknowledgements 
We are grateful for the support from Grants-in-Aid for Scientific Research from the Ministry 
of Education, Cultures, Sports, Science, and Technology, Japan. 
www.intechopen.com
 




Banerjee, S., Wang, Z., Kong, D. & Sarkar, FH. (2009) 3,3'-Diindolylmethane enhances 
chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer 
Research,Vol.69, No.13, (July 2009), pp. 5592-5600, ISSN 1538-7445 
Benzakour, O. & Kanthou, C. (2000) The anticoagulant factor, protein S, is produced by 
cultured human vascular smooth muscle cells and its expression is up-regulated by 
thrombin. Blood. Vol.95, No.6, (March 2000), pp. 2008-2014, ISSN 0006-4971  
Bookman, MA., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, JB. & Fields, SZ. 
(1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-
label phase II study in patients treated after prior chemotherapy that contained 
cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology, Vol.16, No.10, 
(October 1998), pp. 3345-3352, ISSN 0732-183X 
Budman, DR., Tai, J., Calabro, A. & John, V. (2010) The histone deacetylase inhibitor 
panobinostat demonstrates marked synergy with conventional chemotherapeutic 
agents in human ovarian cancer cell lines. Investigational New Drugs, (May 2010), 
published on line: June 9, ISSN 0167-6997  
Chintharlapalli, S., Burghardt, R., Papineni, S., Ramaiah, S., Yoon, K. & Safe, S. (2005) 
Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted 
phenyl)methanes induces apoptosis through nuclear pathways. The Journal of 
Biolical Chemistry, Vol.280, No.26, (July 2005), pp. 24903-24914, ISSN 0021-9258  
Cho, SD., Yoon, K., Chintharlapalli, S., Abdelrahim, M., Lei, P., Hamilton, S., Khan, S., 
Ramaiah, SK. & Safe, S. (2007) Nur77 agonists induce proapoptotic genes and 
responses in colon cancer cells through nuclear receptor-dependent and nuclear 
receptor-independent pathways. Cancer Research, Vol.67, No.2, (January 2007), pp. 
674-683, ISSN 1538-7445 
Cockayne, S., Adamson, J., Lanham-New, S., Shearer, MJ., Gilbody, S. & Torgerson, DJ. 
(2006) Vitamin K and the prevention of fractures: systematic review and meta-
analysis of randomized controlled trials. Archives of  Internal Medicine, Vol.166, 
No.12, (June 2006), pp. 1256-1261, ISSN 0003-9926  
Fujita, H., Tomiyama, J. & Tanaka, T. (1998) Vitamin K2 combined with all-trans retinoic 
acid induced complete remission of relapsing acute promyelocytic leukemia. British 
Journal of Haematology, Vol.103, No.2, (November 1998), pp. 584-585, ISSN 0007-1048  
Geleijnse, JM., Vermeer, C., Grobbee, DE., Schurgers, LJ., Knapen, MH., van der Meer, IM., 
Hofman, A. & Witteman, JC. (2004) Dietary intake of menaquinone is associated 
with a reduced risk of coronary heart disease: the Rotterdam Study. The Journal of 
Nutrition, Vol.134, No.11, (November 2004), pp. 3100-3015, ISSN 0022-3166 
Giaccone, G. (2000) Clinical perspectives on platinum resistance. Drugs, Vol.59, Suppl. 4, pp. 
9-17, ISSN 0012-6667 
Habu, D., Shiomi, S., Tamori, A., Takeda, T., Tanaka, T., Kubo, S. & Nishiguchi, S. (2004) 
Role of vitamin K2 in the development of hepatocellular carcinoma in women with 
viral cirrhosis of the liver. The Journal of the Amerian Medical Association, Vol.292, 
No.3, (July 2004), pp. 358-361, ISSN 0098-7484 
Harries, M., Moss, C., Perren, T., Gore, M., Hall, G., Everard, M., A'Hern, R., Gibbens, I., 
Jenkin, A., Shah, R., Cole, C., Pizzada, O. & Kaye, S. (2004) A phase II feasibility 
study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as 
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
270 
first-line treatment for ovarian cancer. British Journal of Cancer, Vol.91, No.4, 
(August 2004), pp. 627-632, ISSN 0007-0920 
Hartwig, A., Groblinghoff, UD., Beyersmann, D., Natarajan, AT., Filon, R. & Mullenders, 
LH. (1997) Interaction of arsenic (III) with nucleotide excision repair in UV-
irradiated human fibroblasts. Carcinogenesis, Vol.18, No.2, (February 1997), pp. 399-
405, ISSN 0143-3334 
Hennessy, BT., Coleman, RL. & Markman, M. (2009) Ovarian cancer. Lancet, Vol.374, 
No.9698, (October 2009), pp. 1371-1382, ISSN 0140-6736 
Holmes, WF., Soprano, DR. & Soprano, KJ. (2002) Elucidation of molecular events mediating 
induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian 
carcinoma cell line. The Journal of Biological Chemistry, Vol.277, No.47, (November 
2002), pp. 45408-45419, ISSN 0021-9258 
Holmes, WF., Soprano, DR &, Soprano, KJ. (2004) Synthetic retinoids as inducers of 
apoptosis in ovarian carcinoma cell lines. Journal of Cellular Physiology, Vol.199, 
No.3, (June 2004), pp. 317-329, ISSN 0021-9541 
Jung, P., Menssen, A., Mayr, D. & Hermeking, H. (2008) AP4 encodes a c-MYC-inducible 
repressor of p21. Proceedings of the Nationall Academy of Sciences of the United States of 
America, Vol.105, No.39, (September 2008), pp. 15046-15051, ISSN 0027-8424 
Kartalou, M. & Essigmann, JM. (2001) Mechanisms of resistance to cisplatin. Mutation 
Research, Vol.478, No. 1-2, (July 2001), pp. 23-43, ISSN 0027-5107 
Li, H., Kolluri, SK., Gu, J., Dawson, MI., Cao, X., Hobbs, PD., Lin, B., Chen, G., Lu, J., Lin, F., 
Xie, Z., Fontana, JA., Reed, JC. & Zhang, X. (2000) Cytochrome c release and 
apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. 
Science. Vol.289, No.5482, (August 2000), pp. 1159-1164, ISSN 1095-9203 
Li, Y., Lin, B., Agadir, A., Liu, R., Dawson, MI., Reed, JC., Fontana, JA., Bost, F., Hobbs, PD., 
Zheng, Y., Chen, GQ., Shroot, B., Mercola, D. & Zhang, XK. (1998) Molecular 
determinants of AHPN (CD437)-induced growth arrest and apoptosis in human 
lung cancer cell lines. Molecular and Cellular Biology, Vol.18, No.8, (August 1998), pp. 
4719-4731, ISSN 0270-7306 
Liu, J., Zhou, W., Li, SS., Sun, Z., Lin, B., Lang, YY., He, JY., Cao, X., Yan, T., Wang, L., Lu, J., Han, 
YH., Cao, Zhang, XK. & Zeng, JZ. (2008) Modulation of orphan nuclear receptor Nur77-
mediated apoptotic pathway by acetylshikonin and analogues. Cancer Research, Vol.68, 
No.21, (November 2008), pp. 8871-8880, ISSN 1538-7445 
Liu, JJ., Zeng, HN., Zhang, LR., Zhan, YY., Chen, Y., Wang, Y., Wang, J., Xiang, SH., Liu, 
WJ., Wang, WJ., Chen, HZ., Shen, YM., Su, WJ., Huang, PQ., Zhang, HK. & Wu, Q. 
(2010) A unique pharmacophore for activation of the nuclear orphan receptor 
Nur77 in vivo and in vitro. Cancer Research, Vol.70, No.9, (May 2010), pp. 3628-3637, 
ISSN 1538-7445 
Luo, H., Daddysman, MK., Rankin, GO., Jiang, BH. & Chen, YC. (2010) Kaempferol 
enhances cisplatin's effect on ovarian cancer cells through promoting apoptosis 
caused by down regulation of cMyc. Cancer Cell International, Vol. 10, (May 2010), 
pp. 16-25, ISSN 1475-2867 
Masuda, Y., Nakaya, M., Aiuchi, T., Hashimoto, S., Nakajo, S. & Nakaya, K. (2000) The 
mechanism of geranylgeraniol-induced apoptosis involves activation, by a caspase-
3-like protease, of a c-jun N-terminal kinase signaling cascade and differs from 
www.intechopen.com
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
271 
mechanisms of apoptosis induced by conventional chemotherapeutic drugs. 
Leukemia Research, Vol.24, No.11, (November 2000), pp. 937-950, ISSN 0145-2126 
Miyazawa, K., Nishimaki, .J, Ohyashiki, K., Enomoto, S., Kuriya, S., Fukuda, R., Hotta, T., 
Teramura, M., Mizoguchi, H., Uchiyama, T. & Omine, M. (2000) Vitamin K2 
therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid 
leukemia: information through a questionnaire survey of multi-center pilot studies 
in Japan. Leukemia, Vol.14, No.6, (June 2000), pp. 1156-1157, ISSN 0887-6924 
Miyazawa, K., Yaguchi, M., Funato, K., Gotoh, A., Kawanishi, Y., Nishizawa,Y., You, A. & 
Ohyashiki, K. (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on 
HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia, Vol.15, 
No.7, (July 2001), pp. 1111-1117, ISSN 0887-6924 
Mizuta, T., Ozaki, I., Eguchi, Y., Yasutake, T., Kawazoe, S., Fujimoto, K. & Yamamoto, K. 
(2006) The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and 
survival in patients with hepatocellular carcinoma after curative treatment: a pilot 
study. Cancer, Vol.106, No.4, (February 2006), pp. 867-872, ISSN 0008-543X 
Nimptsch, K., Rohrmann, S., Kaaks, R. & Linseisen, J. (2010) Dietary vitamin K intake in 
relation to cancer incidence and mortality: results from the Heidelberg cohort of the 
European Prospective Investigation into Cancer and Nutrition (EPIC-Heidelberg). 
The American Journal of Clinical Nutrition, Vol.91, No.5, (May 2010), pp. 1348-1358, 
ISSN 0002-9165  
Nishikawa, Y., Carr, BI., Wang, M., Kar, S., Finn, F., Dowd, P., Zheng, ZB., Kerns, J. & 
Naganathan S. (1995) Growth inhibition of hepatoma cells induced by vitamin K 
and its analogs. The Jounal of Biological Chemistry, Vol.270, No.47, (November 1995), 
pp. 28304-28310, ISSN 0021-9258 
Nishimaki, J., Miyazawa, K., Yaguchi, M., Katagiri, T., Kawanishi, Y., Toyama, K., 
Ohyashiki, K., Hashimoto, S., Nakaya, K. & Takiguchi, T. (1999) Vitamin K2 
induces apoptosis of a novel cell line established from patient with myelodysplastic 
syndrome in blastic transformation. Leukemia, Vol.13, No.9, (September 1999), pp. 
1399-1405, ISSN 0887-6924 
Ohizumi, H., Masuda, Y., Nakajo, S., Sakai, I., Ohsawa, S. & Nakaya, K. (1995) 
Geranylgeraniol is a potent inducer of apoptosis in tumor cells. Journal of 
Biochemistry, Vol.117, No.1, (January 1995), pp. 11-13, ISSN 0021-924X 
Olson, RE. (2000) Osteoporosis and vitamin K intake. The American Journal of Clinical 
Nutrition, Vol.71, No.5, (May 2000), pp. 1031-1032, ISSN 0002-9165 
Otsuka, M., Kato, N., Shao, RX., Hoshida, Y., Ijichi, H., Koike, Y., Taniguchi, H., Moriyama, 
M., Shiratori, Y., Kawabe, T. & Omata, M. (2004) Vitamin K2 inhibits the growth 
and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. 
Hepatology, Vol.40, No.1, (July 2004), pp. 243-251, ISSN 0270-9139 
Parkin, DM., Bray, F., Ferlay, J. & Pisani, P. (2005) Global Cancer Statics, 2002. A Cancer 
Journal for Clinicians, Vol.55, No. 2, (March-April 2005), pp. 74-108, ISSN 0007-9235 
Pekarsky, Y., Hallas, C., Palamarchuk, A., Koval, A., Bullrich, F., Hirata, Y., Bichi, R., 
Letofsky, J. & Croce, CM. (2001) Akt phosphorylates and regulates the orphan 
nuclear receptor Nur77. Proceedings of the National Academy of  Sciences United States 
of America, Vol. 98, No. 7, (March 2001), pp. 3690-3694, ISSN 0027-8424 
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
272 
Ramaswamy, S., Ross, KN., Lander, ES. & Golub, TR. (2003) A molecular signature of 
metastasis in primary solid tumors. Nature Genetics, Vol.33, No.1, (January 2003), 
pp. 49-54, ISSN 1061-4036 
Raymond, E., Faivre, S., Weiss, G., McGill, J., Davidson, K., Izbicka, E., Kuhn, JG., Allred, C., 
Clark, GM. & Von Hoff, DD. (2001) Effects of hydroxyurea on extrachromosomal 
DNA in patients with advanced ovarian carcinomas. Clinical Cancer Research, Vol.7, 
No.5, (May 2001), pp. 1171-1180, ISSN 1078-0432 
Sakai, I., Hashimoto, S., Yoda, M., Hida, T., Ohsawa, S., Nakajo, S. & Nakaya, K. (1994) 
Novel role of vitamin K2: a potent inducer of differentiation of various human 
myeloid leukemia cell lines. Biochemical and Biophysical Research Communications, 
Vol.205, No.2, (December 1994), pp. 1305-1310, ISSN 0006-291X 
Sargent, JM., Elgie, AW., Williamson, CJ. & Taylor, CG. (1996) Aphidicolin markedly 
increases the platinum sensitivity of cells from primary ovarian tumours. British 
Journal of Cancer, Vol.74, No.11, (December 1996), pp. 1730-1733, ISSN 0007-0920 
Shanahan, CM., Proudfoot, D., Farzaneh-Far, A. & Weissberg, PL. (1998) The role of Gla 
proteins in vascular calcification. Critical Reviews in Eukaryotic Gene Expression, 
Vol.8, No.3-4, (1998), pp. 357-375, ISSN 1045-4403 
Shearer, MJ., Bach, A. & Kohlmeier, M. (1996) Chemistry, nutritional sources, tissue 
distribution and metabolism of vitamin K with special reference to bone health. 
The Journal of Nutrition, Vol.126, Suppl.4, (April 1996), pp. 1181S-1186S, ISSN 0022-
3166 
Schurgers, LJ. & Vermeer, C.(2000) Determination of phylloquinone and menaquinones in 
food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis, 
Vol.30, No.6, (November-December 2000), pp. 298-307, ISSN 0301-0147 
Shibayama-Imazu, T., Sakairi, S., Watanabe, A., Aiuchi, T., Nakajo, S. & Nakaya, K. (2003) 
Vitamin K2 selectively induced apoptosis in ovarian TYK-nu and pancreatic MIA 
PaCa-2 cells out of eight solid tumor cell lines through a mechanism different from 
geranylgeraniol. Journal of Cancer Research and Clinical Oncology, Vol.129, No.1, 
(January 2003), pp. 1-11, ISSN 0170-5216 
Shibayama-Imazu, T., Sonoda, I., Sakairi, S., Aiuchi, T., Ann, WW., Nakajo, S., Itabe, H. & 
Nakaya, K. (2006) Production of superoxide and dissipation of mitochondrial 
transmembrane potential by vitamin K2 trigger apoptosis in human ovarian cancer 
TYK-nu cells. Apoptosis, Vol.11, No.9, (September 2006 ), pp. 1535-1543, ISSN 1360-
8185 
Shibayama-Imazu, T., Fujisawa, Y., Masuda, Y., Aiuchi, T., Nakajo, S., Itabe, H. & Nakaya, 
K. (2008) Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is 
associated with an increase in the level of TR3/Nur77 and its accumulation in 
mitochondria and nuclei. Journal of Cancer Research and Clinical Oncology, Vol.134, 
No.7, (January 2008), pp. 803-812, ISSN 0170-52168  
Shipp, MA., Ross, KN., Tamayo, P., Weng, AP., Kutok, JL., Aguiar, RC., Gaasenbeek, M., 
Angelo, M., Reich, M., Pinkus, GS., Ray, TS., Koval, MA., Last, KW., Norton, A., 
Lister, TA., Mesirov, J., Neuber, DS., Lander, ES., Aster, JC. & Golub, TR. (2002) 
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling 
and supervised machine learning. Nature Medicine, Vol.8, No.1, (January 2002), pp. 
68-74, ISSN 1078-8956 
www.intechopen.com
 
Vitamin K2 as a Chemotherapeutic Agent for Treating Ovarian Cancer 
 
273 
Shiraki, M., Shiraki, Y., Aoki, C. & Miura, M. (2000) Vitamin K2 (menatetrenone) effectively 
prevents fractures and sustains lumbar bone mineral density in osteoporosis. 
Journsl of Bone and Mineral Research, Vol.15, No.3, (March 2000), pp. 515-521, ISSN 
0884-0431 
Soignet, SL., Maslak, P., Wang, ZG., Jhanwar, S., Calleja, E., Dardashti, LJ., Corso, D., 
DeBlasio, A., Gabrilove, J., Scheinberg, DA., Pandolfi, PP. & Warrell, RP. Jr. (1998) 
Complete remission after treatment of acute promyelocytic leukemia with arsenic 
trioxide. The New England Journal of Medicine, Vol.339, No.19, (November 1998), pp. 
1341-1348, ISSN 0028-4793 
Swinnen, LJ., Rankin, C., Carraway, H., Albain, KS., Townsend, JJ., Budd, GT., Kish, JA., 
Rivkin, SE. & Blumenthal, DT. (2008) A phase II study of cisplatin preceded by a 
12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside 
(Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group 
S9149). Journal of Neuro-oncology, Vol.86, No.3, (February 2008), pp. 353-358, ISSN 
0167-594X 
Swisher, EM., Mutch, DG., Rader, JS., Elbendary, A. & Herzog, TJ. (1997) Topotecan in 
platinum- and paclitaxel-resistant ovarian cancer. Gynecologic Oncology. Vol.66, 
No.3, (September 1997), pp. 480-486, ISSN 0090-8258 
Takami, A., Nakao, S., Ontachi, Y., Yamauchi, H. & Matsuda, T. (1999) Successful therapy of 
myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. International 
Journal of Hematology, Vol.69, No.1, (January 1999), pp. 24-26, ISSN 0925-5710 
Tamori, A., Habu, D., Shiomi, S., Kubo, S. & Nishiguchi, S. (2007) Potential role of vitamin 
K2 as a chemopreventive agent against hepatocellular carcinoma. Hepatology 
Research, Vol.37, Suppl.2, (September 2007), pp. S303-S307, ISSN 1386-6346 
Thijssen, HH. & Drittij-Reijnders, MJ. (1996) Vitamin K status in human tissues: tissue-
specific accumulation of phylloquinone and menaquinone-4. British Journal of 
Nutrition, Vol.75, No.1, (January 1996), pp. 121-127 
Tokita, H., Tsuchida, A., Miyazawa, K., Ohyashiki, K., Katayanagi, S., Sudo, H., Enomoto, 
M., Takagi, Y. & Aoki, T. (2006) Vitamin K2-induced antitumor effects via cell-cycle 
arrest and apoptosis in gastric cancer cell lines. International Journal of Molecular 
Medicine. Vol.17, No.2, (February 2006), pp. 235-243, ISSN 1107-3756 
Touma, R., Kartarius, S., Harlozinska, A., Götz, C. & Montenarh, M. (2006) Growth 
inhibition and apoptosis induction in ovarian cancer cells. International Journal of 
Oncology, Vol.29, No.2, (August 2006), pp. 481-488, ISSN 1019-6439 
Tsunetoh, S., Terai, Y., Sasaki, H., Tanabe, A., Tanaka, Y., Sekijima, T., Fujioka, S., 
Kawaguchi, H., Kanemura, M., Yamashita, Y. & Ohmichi, M. (2010) Topotecan as a 
molecular targeting agent which blocks the Akt and VEGF cascade in platinum-
resistant ovarian cancers. Cancer Biology & Therapy. Vol. 10, No.11, (December 2010), 
pp. 1137-1146, ISSN 1538-4047 
Uslu, R., Sanli, UA., Sezgin, C., Karabulut, B, Terzioglu, E., Omay, SB. & Goker, E. (2000) 
Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian 
carcinoma cell lines. Clinical Cancer Research, Vol.6, No.12, (December 2000), pp. 
4957-4964, ISSN 1078-0432 
Vivanco, I. & Sawyers, CL. (2002) The phosphatidylinositol 3-Kinase AKT pathway in 




Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
274 
Wu, FY., Liao, WC. & Chang, HM. (1993) Comparison of antitumor activity of vitamins K1, 
K2 and K3 on human tumor cells by two (MTT and SRB) cell viability assays. Life 
Sciences, Vol.52, No.22, (March 1993), pp. 1797-1804, ISSN 0024-3205 
Wu, Q., Liu, S., Ye, XF., Huang, ZW. & Su, WJ. (2002) Dual roles of Nur77 in selective 
regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. 
Carcinogenesis, Vol.23, No.10, (October 2002), pp. 1583-1592, ISSN 0143-3334 
Yaguchi, M., Miyazawa, K., Katagiri, T., Nishimaki, J., Kizaki, M., Tohyama, K. & Toyama, 
K. (1997) Vitamin K2 and its derivatives induce apoptosis in leukemia cells and 
enhance the effect of all-trans retinoic acid. Leukemia, Vol.11, No.6, (June 1997), pp. 
779-787, ISSN 0887-6924  
Yaguchi, M., Miyazawa, K., Otawa, M., Katagiri, T., Nishimaki, J., Uchida, Y., Iwase, O., 
Gotoh, A., Kawanishi, Y. & Toyama, K. (1998) Vitamin K2 selectively induces 
apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of 
apoptotic cells using APO2.7 monoclonal antibody. Leukemia, Vol.12, No.9, 
(September 1998), pp. 1392-1397, ISSN 0887-6924 
Yaguchi, M., Miyazawa, K., Otawa, M., Ito, Y., Kawanishi, Y. & Toyama, K. (1999) Vitamin 
K2 therapy for a patient with myelodysplastic syndrome. Leukemia, Vol.13, No.1, 
(January 1999), pp. 144-145, ISSN 0887-6924 
Yallapu, MM., Maher, DM., Sundram, V., Bell, MC., Jaggi, M. & Chauhan, SC. (2010) 
Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin 
nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research, Vol.3, 
(April 2010), pp. 11-23, ISSN 1757-2215 
Yokoyama, T., Miyazawa, K., Yoshida, T. & Ohyashiki, K. (2005) Combination of vitamin K2 
plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer 
cell lines. International Journal of Oncology, Vol.26, No.1, (January 2005), pp. 33-40, 
ISSN 1019-6439 
Yoshiji, H., Noguchi, R., Toyohara, M., Ikenaka, Y., Kitade, M., Kaji, K., Yamazaki, M., 
Yamao, J., Mitoro, A., Sawai, M., Yoshida, M., Fujimoto, M., Tsujimoto, T., 
Kawaratani, H., Uemura, M. & Fukui, H. (2009) Combination of vitamin K2 and 
angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of 
hepatocellular carcinoma. Journal of Hepatology, Vol.51, No.2, (August 2009), pp. 
315-321, ISSN 0168-8278 
Yoshida, T., Miyazawa, K., Kasuga, I., Yokoyama, T., Minemura, K., Ustumi, K., Aoshima, 
M. & Ohyashiki, K. (2003) Apoptosis induction of vitamin K2 in lung carcinoma 
cell lines: the possibility of vitamin K2 therapy for lung cancer. International Journal 
of Oncoogy, Vol.23, No.3, (September 2003), pp. 627-632, ISSN 1019-6439 
www.intechopen.com
Ovarian Cancer - Clinical and Therapeutic Perspectives
Edited by Dr. Samir Farghaly
ISBN 978-953-307-810-6
Hard cover, 338 pages
Publisher InTech
Published online 15, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Worldwide, Ovarian carcinoma continues to be responsible for more deaths than all other gynecologic
malignancies combined. International leaders in the field address the critical biologic and basic science issues
relevant to the disease. The book details the molecular biological aspects of ovarian cancer. It provides
molecular biology techniques of understanding this cancer. The techniques are designed to determine tumor
genetics, expression, and protein function, and to elucidate the genetic mechanisms by which gene and
immunotherapies may be perfected. It provides an analysis of current research into aspects of malignant
transformation, growth control, and metastasis. A comprehensive spectrum of topics is covered providing up to
date information on scientific discoveries and management considerations.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
K. Nakaya, Y. Masuda, T. Aiuchi and H. Itabe (2012). Vitamin K2 as a Chemotherapeutic Agent for Treating
Ovarian Cancer, Ovarian Cancer - Clinical and Therapeutic Perspectives, Dr. Samir Farghaly (Ed.), ISBN: 978-
953-307-810-6, InTech, Available from: http://www.intechopen.com/books/ovarian-cancer-clinical-and-
therapeutic-perspectives/vitamin-k2-as-a-chemotherapeutic-agent-for-treating-ovarian-cancer
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
